Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Change in Accured Expenses (2018 - 2025)

10x Genomics' Change in Accured Expenses history spans 8 years, with the latest figure at $4.8 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 8.8% year-over-year to $4.8 million; the TTM value through Dec 2025 reached -$5.2 million, up 59.54%, while the annual FY2025 figure was -$5.2 million, 59.54% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $4.8 million at 10x Genomics, up from -$7.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $19.5 million in Q3 2023 and bottomed at -$15.1 million in Q1 2023.
  • The 5-year median for Change in Accured Expenses is -$55500.0 (2022), against an average of -$42650.0.
  • The largest annual shift saw Change in Accured Expenses soared 347.23% in 2021 before it tumbled 2613.86% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $18.9 million in 2021, then plummeted by 97.52% to $469000.0 in 2022, then crashed by 2613.86% to -$11.8 million in 2023, then soared by 137.31% to $4.4 million in 2024, then grew by 8.8% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Change in Accured Expenses are $4.8 million (Q4 2025), -$7.0 million (Q3 2025), and -$7.2 million (Q2 2025).